Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Beamion LUNG-1: An Open Label, Phase I Dose Escalation Trial, With Dose Confirmation and Expansion, of Zongertinib (BI 1810631) as Monotherapy in Patients With Advanced or Metastatic Solid Tumors With HER2 Aberrations

Next Previous
X
Search
Trial Profile

Beamion LUNG-1: An Open Label, Phase I Dose Escalation Trial, With Dose Confirmation and Expansion, of Zongertinib (BI 1810631) as Monotherapy in Patients With Advanced or Metastatic Solid Tumors With HER2 Aberrations

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zongertinib (Primary)
  • Indications Cholangiocarcinoma; Colorectal cancer; Lung cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Beamion Lung 1
  • Sponsors Boehringer Ingelheim

    • Most Recent Events

    • 27 Aug 2024 According to a Boehringer Ingelheim media release, ew data from a primary analysis of the first Cohort of Phase Ib in pre-treated patients with HER2m+ NSCLC to be presented in a Presidential Symposium on Monday, September 9, from 8:30AM - 10:00AM PDT (Location: Plenary Hall) and featured in the official WCLC Press Program.
    • 08 Jul 2024 Planned number of patients changed from 371 to 554.
    • 04 Jun 2024 Results (n=61) demonstrating updated Phase Ia data, including PFS data, and data from Phase Ib Cohort 1 of this study presented at the 60th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top